Asia-Pacific journal of clinical oncology最新文献

{"title":"Prognostic Significance of Deubiquitinase OTUD7B in NK/T-Cell Lymphoma","authors":"Yizhen Liu,&nbsp;Shujuan Wen,&nbsp;Zuguang Xia,&nbsp;Shiyu Jiang,&nbsp;Guangliang Chen,&nbsp;Ailing Gui,&nbsp;Ling Yang,&nbsp;Shune Yang,&nbsp;Xuejun Ma,&nbsp;Qunling Zhang","doi":"10.1111/ajco.70060","DOIUrl":"10.1111/ajco.70060","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>OTUD7B (ovarian tumor domain-containing 7B) is a deubiquitinase that has established prognostic significance in diffuse large B-cell lymphoma and various solid tumors. In our present work, we aimed to explore its role in NK/T cell lymphoma (NKTCL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Expression level of OTUD7B was assessed through immunohistochemistry in 53 NKTCL tissue samples. Statistical analyses were conducted to elucidate correlations between its expression and clinicopathological parameters of patients. Kaplan−Meier survival curves were constructed for survival analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>OTUD7B was overexpressed in 41 (77.4%) NK/T tissue samples. Remarkably, patients with OTUD7B overexpression exhibit improved progression-free survival (PFS) (<i>p</i> = 0.021) and overall survival (OS) compared to those with low OTUD7B expression (<i>p</i> = 0.007). Multivariate Cox regression analysis demonstrated that OTUD7B was an independent prognostic indicator for both PFS (<i>p</i> = 0.037, HR = 0.401, 95% CI: 0.169−0.947) and OS (<i>p</i> = 0.043, HR = 0.278, 95% CI: 0.081−0.961) in NTKCL patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>OTUD7B could act as a prognostic indicator in NTKCL patients; further investigations remain imperative.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"766-771"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Experience of Cabozantinib in Relapsed Osteosarcoma and Ewing Sarcoma-A Single Center Retrospective Study.","authors":"Jiaxing Jason Qin, Susie Bae, Stephen J Luen, Anne Hamilton, Lisa Orme, Eden Andrew, Elizabeth A Connolly, Jeremy Lewin","doi":"10.1111/ajco.70180","DOIUrl":"https://doi.org/10.1111/ajco.70180","url":null,"abstract":"<p><strong>Aim: </strong>Cabozantinib has demonstrated efficacy in advanced osteosarcoma and Ewing sarcoma. This study evaluated its real-world outcomes in patients with relapsed osteosarcoma and Ewing sarcoma within Australia.</p><p><strong>Methods: </strong>Retrospective investigation to evaluate real-world outcomes of cabozantinib in patients with relapsed osteosarcoma or Ewing sarcoma at a high-volume adult sarcoma center in Australia. Eligible patients were identified from a prospectively maintained institutional database. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were clinical benefit rate and treatment-related adverse events (TRAEs).</p><p><strong>Results: </strong>Between 2020 and 2025, 13 osteosarcoma and 2 Ewing sarcoma received cabozantinib. Median follow-up was 12.9 (95% CI 8.6-NR) months. For the osteosarcoma cohort, median PFS was 4.3 (95% CI 2.6-6.9) months and median OS 9.8 (95% CI 6.0-NR) months. One Ewing sarcoma patient was deceased within 1 month of cabozantinib initiation, the other patient maintained tumor response at 5 months after initiation. First- versus later-line use resulted in a median PFS of 5.4 versus 4.2 months, and median OS of 11.2 versus 7.7 months respectively. Clinical benefit rate was 38%. Nine (60%) patients required dose reduction due to TRAEs. Two patients developed pneumothoraces, leading to permanent discontinuation in one. Two patients discontinued due to decline in performance status, all others were due to disease progression. There was no treatment-related mortality.</p><p><strong>Conclusion: </strong>In this single-center Australian analysis, cabozantinib showed activity in relapsed osteosarcoma and Ewing sarcoma with manageable TRAEs. Outcomes were comparable to those reported in the CABONE study and other real-world series.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The International Conference on New Models for Cancer Prevention and Treatment (NMCPT 2026)","authors":"","doi":"10.1111/ajco.70156","DOIUrl":"https://doi.org/10.1111/ajco.70156","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 S3","pages":"S1-S19"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost of Treating Patients Who Undergo Resection of Colorectal Liver Metastases: An Australian Pilot Study","authors":"Nazim Bhimani,&nbsp;Rebecca Seton,&nbsp;David L. Chan,&nbsp;Mbathio Dieng,&nbsp;Patrick J. Kelly,&nbsp;Thomas J. Hugh","doi":"10.1111/ajco.70056","DOIUrl":"10.1111/ajco.70056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The cost of treating cancer, especially metastatic disease, can place a financial burden on patients, caregivers, and the healthcare system. A previous systematic review assessing the cost of treating metastatic colorectal cancer in the era of personalized medicine showed that this was approximately 300,000 USD. Surprisingly, there is little data on the cost of treating patients with colorectal liver metastases (CRLM). The aim of this study was to conduct a pilot cost-of-illness study on patients who undergo liver resection for CRLM in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective cohort study examining the direct medical costs to the healthcare system and out-of-pocket costs to patients who underwent resection for CRLM in 1 year (2018). These costs were calculated in 2022 Australian dollars from the time of the diagnosis of the liver metastases to the time of the last follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 25 patients underwent resection in 2018, but only 16 received all their treatment at the Northern Campus. The median total cost of treating each patient was $328,773.59 (range: $63,244.40–$525,873.10). The highest cost was for medical oncology treatment, with a median of $90,228.87 per patient (range: $2087.06–$241,514.80), followed by liver surgery and consultations, $57,131.76 (range: $12,455.10–$319,178.90), and colorectal surgery and consultations, $55,990.29 (range: $7234.19–$200,755.60). Patients considered to be cured of their disease had a lower median cost than patients who had either died from their disease or were undergoing treatment for recurrent disease ($152,476.50 vs. $351,487.50, <i>p</i> = 0.030).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study demonstrates that the cost of treating patients with CRLM in Australia is moderate but is considerably lower than many other cancer types, especially for those who are cured, reflecting good value care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"749-756"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145538729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quercetin as a Therapeutic Agent for Oral Cancer: Current Evidence and Future Directions","authors":"Hua Sun,&nbsp;Huihui Wang,&nbsp;Shujiang Guo","doi":"10.1111/ajco.70046","DOIUrl":"10.1111/ajco.70046","url":null,"abstract":"<p>Oral cancer, specifically oral squamous cell carcinoma, is rapidly progressive, with a high recurrence rate and grave prognosis. Treatment modalities like surgery, chemotherapy, and radiotherapy are customarily associated with noxious side effects as well as drug resistance. The food constituent flavonoid quercetin has been identified as anticancer through several mechanisms, including apoptosis induction, suppression of metastasis, cell cycle arrest, and chemosensitization. Its clinical application is, however, restricted by poor systemic absorption. Novel nano-formulations such as liposomes, polymeric nanoparticles, etc., have emerged for improving the stability, bioavailability, and therapeutic action of quercetin. Artificial intelligence has also been reported to be of potential use in predicting patient response to quercetin, recognizing new molecular targets, and customizing treatment regimens. Future research should be conducted with clinical trials to establish the effectiveness of quercetin as an adjuvant treatment and fine-tune targeted delivery systems for it. There is a therapeutic promise for quercetin across multiple types of oral cancer due to its multi-targeting potential. Quercetin, in combination with traditional and immunotherapeutic strategies, represents a promising new strategy with the potential to overcome treatment barriers and reduce toxicity in oral cancer management.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"692-704"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Papillary Tumors of the Pineal Region (PTPR) in Pediatric Population: A Case Report and Literature Review","authors":"Beril Balci Topuz,&nbsp;Serra Kamer,&nbsp;Tugce Bozkurt Vardar,&nbsp;Elif Bolat,&nbsp;Eda Ataseven,&nbsp;Yesim Ertan,&nbsp;Taner Akalin","doi":"10.1111/ajco.70010","DOIUrl":"10.1111/ajco.70010","url":null,"abstract":"<p>Papillary tumors of the pineal region (PTPR) are rare central nervous system neoplasms, with a limited number of pediatric cases reported in the literature. Their optimal management remains unclear due to their unpredictable biological behavior and high recurrence rates. This study presents the clinical course, treatment, and long-term follow-up of a 3-year-old child diagnosed with PTPR. Additionally, we conducted a comprehensive review of 35 pediatric cases reported to date, analyzing clinical presentation, treatment strategies, recurrence patterns, and outcomes. The review revealed that gross total resection (GTR) was performed in 69.6% of cases, yet recurrence occurred in 38.8% of these patients. In cases of subtotal resection (STR), the rate of recurrence was significantly higher, with 60% of patients experiencing a relapse. Adjuvant radiotherapy (RT) seems to enhance disease control, especially in cases with STR. Spinal dissemination was observed in 5.7% of cases at diagnosis and 6.2% at recurrence, both of which were associated with poor prognosis. Our case highlights the effectiveness of adjuvant RT for the first time in preventing tumor progression following STR, with long-term disease stability (9 years and 2 months) observed over a 9-year and 6-month follow-up period. PTPRs have a high recurrence rate, which requires careful selection of patients for adjuvant therapies. Although GTR is the standard treatment approach, adjuvant RT may offer additional control in specific cases, particularly for patients with STR or those classified as high-risk. Further research is needed to establish standardized treatment protocols and improve long-term outcomes for pediatric patients with PTPR.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 5","pages":"625-639"},"PeriodicalIF":2.1,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144990939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Augmented Reality, Mixed Reality, Virtual Reality, and Extended Reality Applications in Personalized Oncology and Patient-Centered Cancer Care: A Narrative Review.","authors":"Malarkodi Velraj, Deepalakshmi Mani, Arun Kanniyappan Parthasarathy, Vijayakumar Murugesan, Kommu Pradeep, Surabhi Panneerselvam, Panneerselvam Theivendren","doi":"10.1111/ajco.70172","DOIUrl":"https://doi.org/10.1111/ajco.70172","url":null,"abstract":"<p><strong>Background: </strong>Extended reality (XR) technologies, including augmented reality (AR), mixed reality (MR), and virtual reality (VR), are an appealing technology in clinical oncology. This narrative review evaluates the current evidence of XR applications throughout the cancer care continuum in terms of the clinical implementation, patient outcome, and the relevance of the practice to practicing clinical oncologists.</p><p><strong>Methods: </strong>A literature search on PubMed, Scopus, Web of Science, and Cochrane Library (January 2015-December 2025) was conducted at the right time to select the articles related to AR, VR, MR, XR, and cancer/oncology. Randomized controlled trials (RCTs), systematic reviews, meta-analyses, and clinical implementation studies were given priority.</p><p><strong>Results: </strong>VR contains the strongest evidence base in which 15 RCTs meta-analysis (n = 864) found large reductions in the level of anxiety related to chemotherapy (standardized mean difference [SMD] = -1.40) among adult patients with cancer and fatigue (SMD = -3.85). Cancer-related pain (SMD = -0.86, 95% CI: -1.89 to -0.85, p < 0.001) affected significantly VR interventions as well when implemented in 28 RCTs. In hepatic, glioma, and gastrointestinal tumor resection, AR-guided surgical navigation has been clinically workable, and prospective research has indicated that it is capable of better tumor localization. Depression (SMD = -1.86, p < 0.001) was also reduced. The 3D holographic visualization with the help of MR enables the treatment planning of the multidisciplinary type.</p><p><strong>Conclusions: </strong>The XR technologies possess immense potential in the field of personalized oncology. The sphere of VR-based supportive care intervention is clinically prepared, and still the uses of AR and MR in surgical oncology require confirmation of multicenter trials. Standardization of the protocols, cost-effectiveness studies and its integration into the clinical processes are yet to remain on the list of the top priorities.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Interest to Care: Closing the Psycho-Oncology Loop in Advanced Cancer.","authors":"Po-Jung Hsueh, Lien-Chung Wei","doi":"10.1111/ajco.70179","DOIUrl":"https://doi.org/10.1111/ajco.70179","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Experience of Mandarin-Speaking Radiotherapy Patients Using an Instant Language Translation Device to Facilitate Communication.","authors":"Darren Hunter, Nigel Anderson, Richard Oates, David Kok, Nicola Treffry, Shohani Douglas, Caroline Wright","doi":"10.1111/ajco.70175","DOIUrl":"https://doi.org/10.1111/ajco.70175","url":null,"abstract":"<p><strong>Introduction: </strong>Clear communication between patients and radiation therapists (RTTs) is fundamental to quality radiotherapy (RT) care. This study aimed to evaluate patient experience and satisfaction with the use of an instant language translation device (ITD) to facilitate communication between Mandarin-speaking patients and RTTs.</p><p><strong>Methods: </strong>This multisite study spanned three Australian public hospitals over 2 years. A non-probability purposive sample of Mandarin-speaking radiation therapy patients aged >18 years was recruited. Patients who had received prior RT were excluded. Anonymous surveys gathered scaled and free-text data on participant experience and satisfaction with ITD use. Participant demographics, baseline literacy scores, and information from daily communication log sheets were also collected. Descriptive statistics and correlation analyses (Kruskal-Wallis and Fisher's exact tests) were employed to analyze data.</p><p><strong>Results: </strong>A total of 44 participants were recruited and consented to the study, with four withdrawing. Participants indicated satisfaction with ITD use, inclination to recommend ITD use for others, perception that the ITD enhanced RT, and positive overall care quality. Where participants reported technical issues, Kruskal-Wallis tests demonstrated correlation with; (1) a positive recommendation for daily use (p = 0.024), and (2) perceptions of enhanced RT experience with ITD use (p = 0.008).</p><p><strong>Conclusion: </strong>This research highlights the importance of language concordance with RT patients. The findings support continued use of an ITD for Mandarin-speaking participants within an RT context, despite technical issues. Advancing technologies hold promise for further improvements in translation quality. Future research is required to understand clinical impact of ITD use and the potential for expanded application.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Centre Study.","authors":"Jyothirmaye Kuppa, Nitesh Rao, Rajiv Juneja, Caroline Milton, Shahid Ullah","doi":"10.1111/ajco.70174","DOIUrl":"https://doi.org/10.1111/ajco.70174","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have improved cancer outcomes but can cause immune-related adverse effects (irAEs), including acute kidney injury (AKI). Limited Australian data exists regarding ICI-associated AKI (ICI-AKI). This observational study is aimed to describe the incidence, risk factors, and outcomes of ICI-AKI at Southern Adelaide Local Health Network (SALHN), South Australia.</p><p><strong>Methods: </strong>Adult patients receiving ICI therapy at SALHN between January 2020 and December 2023 were included. Clinical and laboratory data were collected from electronic medical records. ICI-AKI was defined as AKI that led to the delay or discontinuation of ICI therapy due to clinical concern, biopsy-proven ICI-related tubulointerstitial nephritis, or corticosteroid-treated suspected ICI-AKI. Data on kidney biopsy findings, corticosteroid use, ICI rechallenge, AKI recurrence, and renal recovery were assessed.</p><p><strong>Results: </strong>Among 507 patients, 58 (11.4%) developed AKI, with 11 cases (2.2%) attributed to ICIs. Ipilimumab use and lower baseline eGFR were associated with higher AKI and ICI-AKI risk, while durvalumab was associated with lower AKI risk. Median time to AKI onset was 83 days post-first ICI cycle. Corticosteroids were initiated in eight patients for a median of 154 days. Four patients underwent kidney biopsy (median 106 days post-AKI), all showing tubulointerstitial nephritis. Four patients were rechallenged with ICIs; one had recurrent AKI. One patient required dialysis, and two achieved complete renal recovery.</p><p><strong>Conclusions: </strong>In this first Australian study examining all forms of cancer, ICI-AKI occurred infrequently, but had a significant clinical impact. Ipilimumab exposure and impaired baseline kidney function were key risk factors.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148918296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}